
Making Cancer History®

MDAnderson Skin Cancer Screening

Page 1 of 3

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Screening is only intended for asymptomatic individuals. Patient must be a candidate for and is willing to undergo curative treatment.



¹ Patients should monitor their skin for any changes and seek prompt medical evaluation of any lesions concerning for skin cancer

MD Anderson Skin Cancer Screening

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Ebell, M., Epling, J. W., Jr., ... Siu, A. L. (2016). Screening for skin cancer: Us preventive services task force recommendation statement. *JAMA*, 316(4), 429-435. doi:10.1001/jama.2016.8465
- Henrikson, N. B., Ivlev, I., Blasi, P. R., Nguyen, M. B., Senger, C. A., Perdue, L. A., & Lin, J. S. (2023). Skin cancer screening: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*, 329(15), 1296-1307. doi:10.1001/jama.2023.3262
- Herr, M. M., Schonfeld, S. J., Dores, G. M., Withrow, D. R., Tucker, M. A., Curtis, R. E., & Morton, L. M. (2018). Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: Second cancer occurrence and survival. *Journal of the National Cancer Institute*. 110(11), 1248-1258. doi:10.1093/jnci/djy052
- Katalinic, A., Waldmann, A., Weinstock, M. A., Geller, A. C., Eisemann, N., Greinert, R., ... Breitbart, E. (2012). Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. *Cancer*, 118(21), 5395-5402. doi:10.1002/cncr.27566
- Kovalyshyn, I., Dusza, S. W., Siamas, K., Halpern, A. C., Argenziano, G., & Marghoob, A. A. (2011). The impact of physician screening on melanoma detection. *Archives of Dermatology*, 147(11), 1269-1275. doi:10.1001/archdermatol.2011.181
- Lazovich, D., Vogel, R. I., Berwick, M., Weinstock, M. A., Anderson, K. E., & Warshaw, E. M. (2010). Indoor tanning and risk of melanoma: A case-control study in a highly exposed population. *Cancer Epidemiology and Prevention Biomarkers*, 19(6), 1575-1568. doi:10.1158/1055-9965.EPI-09-1249
- Omland, S. H. Ahlström, M. G., Gerstoft, J., Pedersen, G., Mohey, R., Pedersen, C., ... Obel, N. (2018). Risk of skin cancer in patients with HIV: A Danish nationwide cohort study. *Journal of the American Academy of Dermatology*, 79(4), 689-695. doi:10.1016/j.jaad.2018.03.024

MD Anderson Skin Cancer Screening

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This screening algorithm is based on majority expert opinion of the Skin Screening workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Lead

Therese Bevers, MD (Cancer Prevention)

Workgroup Members

Susan Chon, MD (Dermatology)

Ana Ciurea, MD (Dermatology)

Olga N. Fleckenstein, BS

Saira J. George, MD (Dermatology)

Ernest Hawk, MD, MPH (Cancer Prevention)

Kelly Nelson, MD (Dermatology)

Omar Pacha, MD (Dermatology)

Anisha Patel, MD (Dermatology)

Eduardo Vilar Sanchez, MD, PhD (Cancer Prevention)

Hannah Warr, MSN, RN, CPHON

Clinical Effectiveness Development Team